Covered recipient · General Payments record
GERARDO W HIZON
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,823.47
- Reported across 77 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $371.82 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Abbott Laboratories | $105.08 | 5 |
| Lilly USA, LLC | $68.38 | 3 |
| Acerta Pharma LLC | $68.27 | 3 |
| VIVUS LLC | $47.15 | 2 |
| Novo Nordisk AS | $43.85 | 2 |
| GlaxoSmithKline, LLC. | $23.56 | 1 |
| Amgen Inc. | $15.53 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $22.79 | 07/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124900641 | CMS |
| Abbott Laboratories | $17.65 | 09/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124900649 | CMS |
| Abbott Laboratories | $24.07 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124900643 | CMS |
| Abbott Laboratories | $23.69 | 10/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124900645 | CMS |
| Abbott Laboratories | $16.88 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124900647 | CMS |
| Amgen Inc. | $15.53 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117278332 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.80 | 05/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104735449 | CMS |
| AstraZeneca Pharmaceuticals LP | $21.58 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104753978 | CMS |
| AstraZeneca Pharmaceuticals LP | $22.89 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104392661 | CMS |
| GlaxoSmithKline, LLC. | $23.56 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116208094 | CMS |
| Lilly USA, LLC | $20.75 | 05/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135000954 | CMS |
| Lilly USA, LLC | $26.85 | 07/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135008077 | CMS |
| Lilly USA, LLC | $20.78 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1134986770 | CMS |
| Novo Nordisk Inc | $21.63 | 08/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097039656 | CMS |
| Novo Nordisk Inc | $22.22 | 09/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097148217 | CMS |
| VIVUS LLC | $24.12 | 08/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129416108 | CMS |
| VIVUS LLC | $23.03 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129416110 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.